Sparks - SynAct Pharma

SynAct Pharma reported Q226 operating expenses of SEK24.6m, down 19% y-o-y, while the net loss narrowed to SEK22.0m and quarter-end cash stood at SEK14.2m. Post-period, the company secured a new financing facility of up to SEK100m from Fenja Capital, initially drawing SEK50m as convertible loans on more favourable terms than its previous SEK40m Hunter Capital facility, which has been terminated. Management reports a cash runway into Q327, providing greater flexibility to progress Phase III readiness for lead asset resomelagon and partnering activities.

Operationally, Q2 was defined by the ADVANCE Phase IIb readout in rheumatoid arthritis. While the primary DAS28-CRP endpoint was missed, encouraging American College of Rheumatology 20% response (ACR20), Simplified Disease Activity Index (SDAI) and C-reactive protein (CRP) effects at 40mg, alongside favourable tolerability, support Phase III planning and partnering discussions. Preparations for End-of-Phase II regulatory interactions with the FDA and EMA are progressing in H226.

Post-period, SynAct also signed a term sheet with Brazilian pharmaceutical company Hipolabor, potentially paving the way for resomelagon’s first commercial partnership in dengue. RESOVIR-2 is being amended, with the second part expected to recruit during the H127 dengue season, while RESPIRE has added New Zealand sites to mitigate seasonal recruitment challenges. Collectively, these developments underscore resomelagon’s broader potential across autoimmune and inflammatory diseases and as a host-directed therapy in viral infections.